ACS Nano · 2020 · 57 citations · 42 references
PharmacyOncologyPharmaceuticsDrug DeliveryNanoparticle Drug DeliveryTargeted Drug DeliveryCancer Drug DeliveryCancer NanomedicineNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineTherapeutic Protein EngineeringActive Tumor TargetingHydrophobic Drug LoadingNanoparticlesProtein-based NanoparticlesTherapeutic Targeting Of Fusion ProteinsTumor Tissue TargetingTumor Vasculature TargetingTumor-targeted Drug Delivery
Human serum albumin (HSA) has the characteristics of biocompatibility and long circulation, which is widely used as the carrier of insoluble anticancer drugs, but it also has some disadvantages such as weak tumor targeting and uncontrollable drug release. Herein, HSA was modified to improve its biological performance by introducing polyhistidine (pHis), matrix metalloproteinase-2 (MMP-2) digestion, and Arg-Gly-Asp (RGD) peptide at the separated end of HSA through gene fusion technology. The resulting protein expressed by Pichia pastoris could self-assemble into 3RGD-HSA-MMP-18His nanoparticles (RHMH18 NPs) accompanied by loading hydrophobic drug paclitaxel (PTX) into the polyhistidine micelle core. RHMH18 NPs exhibited active tumor targeting in high efficiency owing to the RGD-mediated specific binding toward ανβ3-integrin upregulated on tumor vasculature endothelium, resulting in the enrichment of therapeutic substances in tumor sites. Once reaching the tumor microenvironment, RHMH18 NPs was cut off by MMP-2 to remove the HSA-3RGD moiety, leaving the small and positively charged histidine micelle, which could penetrate the deep part of tumor tissue more effectively. Finally, the histidine micelle escaped from lysosome successfully and released drug in response to pH. The in vivo experiments’ results demonstrated that the three-stage propulsion RHMH18 NPs presented superior tumor inhibition activity with minimal side effects, providing potential strategies of protein based drug delivery systems for tumor therapy.
42
A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo
Suping Li, Qiao Jiang, Shaoli Liu et al. · Nature Biotechnology · 2018 · 1.5K citations
Neil Desai, Vuong Trieu, Zhiwen Yao et al. · Clinical Cancer Research · 2006 · 1.2K citations
Medicine, Oncology, Pharmacology +14
Enzyme-activatable polymer–drug conjugate augments tumour penetration and treatment efficacy
Quan Zhou, Shiqun Shao, Jinqiang Wang et al. · Nature Nanotechnology · 2019 · 813 citations
Pharmacy, Oncology, Pharmaceutics +12
DNA Origami as an <i>In Vivo</i> Drug Delivery Vehicle for Cancer Therapy
Qian Zhang, Qiao Jiang, Na Li et al. · ACS Nano · 2014 · 658 citations
Pharmacy, Oncology, Pharmaceutics +17